Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jandeleit

Showing results (11-20 of 190) with videos related to

Pageof 19
Sort By:
Current Drug Targets. Cardiovascular & Haematological Disorders|March 1, 2006
Preventing atherosclerosis with angiotensin-converting enzyme inhibitors: emphasis on diabetic atherosclerosisT J Allen, K A Jandeleit-Dahm
Kidney International. Supplement|July 1, 1993
Intrarenal renin-angiotensin system in renal physiology and pathophysiologyC I Johnston, B Fabris, K Jandeleit
Diabetologia|October 12, 2012
Insulin and cardiovascular disease: biomarker or association?K A M Jandeleit-Dahm, S P Gray
Current Hypertension Reports|September 3, 2004
Antiproteinuric effect of RAS blockade: new mechanismsMarkus Lassila, Mark E Cooper, Karin Jandeleit-Dahm
Diabetes & Metabolism|January 3, 2015
Beyond Glycosuria: Exploring the intrarenal effects of SGLT₋₂ inhibition in diabetesM C Thomas, K Jandeleit-Dahm, F Bonnet
Current Pharmaceutical Design|October 30, 2015
The role of NADPH oxidase in vascular disease--hypertension, atherosclerosis & strokeStephen P Gray, Karin A M Jandeleit-Dahm
Current Diabetes Reports|December 1, 2005
Lipids and diabetic renal diseaseMark E Cooper, Karin A M Jandeleit-Dahm
Handbook of Experimental Pharmacology|August 19, 2020
Inhibitors of Advanced Glycation End Product (AGE) Formation and AccumulationKarly C Sourris, Anna Watson, Karin Jandeleit-Dahm
Current Opinion in Nephrology and Hypertension|November 30, 2011
The endothelin system and endothelin receptor antagonistsKarin A M Jandeleit-Dahm, Anna M D Watson
Diabetes|December 22, 2016
Platelet Hyperreactivity in Diabetes: Focus on GPVI Signaling-Are Useful Drugs Already Available?Jane F Arthur, Karin Jandeleit-Dahm, Robert K Andrews
Pageof 19

Showing results (11-20 of 190) with videos related to

Sort By:
Pageof 19
Current Drug Targets. Cardiovascular & Haematological Disorders|March 1, 2006
Preventing atherosclerosis with angiotensin-converting enzyme inhibitors: emphasis on diabetic atherosclerosisT J Allen, K A Jandeleit-Dahm
Kidney International. Supplement|July 1, 1993
Intrarenal renin-angiotensin system in renal physiology and pathophysiologyC I Johnston, B Fabris, K Jandeleit
Diabetologia|October 12, 2012
Insulin and cardiovascular disease: biomarker or association?K A M Jandeleit-Dahm, S P Gray
Current Hypertension Reports|September 3, 2004
Antiproteinuric effect of RAS blockade: new mechanismsMarkus Lassila, Mark E Cooper, Karin Jandeleit-Dahm
Diabetes & Metabolism|January 3, 2015
Beyond Glycosuria: Exploring the intrarenal effects of SGLT₋₂ inhibition in diabetesM C Thomas, K Jandeleit-Dahm, F Bonnet
Current Pharmaceutical Design|October 30, 2015
The role of NADPH oxidase in vascular disease--hypertension, atherosclerosis & strokeStephen P Gray, Karin A M Jandeleit-Dahm
Current Diabetes Reports|December 1, 2005
Lipids and diabetic renal diseaseMark E Cooper, Karin A M Jandeleit-Dahm
Handbook of Experimental Pharmacology|August 19, 2020
Inhibitors of Advanced Glycation End Product (AGE) Formation and AccumulationKarly C Sourris, Anna Watson, Karin Jandeleit-Dahm
Current Opinion in Nephrology and Hypertension|November 30, 2011
The endothelin system and endothelin receptor antagonistsKarin A M Jandeleit-Dahm, Anna M D Watson
Diabetes|December 22, 2016
Platelet Hyperreactivity in Diabetes: Focus on GPVI Signaling-Are Useful Drugs Already Available?Jane F Arthur, Karin Jandeleit-Dahm, Robert K Andrews
Pageof 19